HK1212224A1 - A stabilized pemetrexed formulation - Google Patents
A stabilized pemetrexed formulationInfo
- Publication number
- HK1212224A1 HK1212224A1 HK16100181.1A HK16100181A HK1212224A1 HK 1212224 A1 HK1212224 A1 HK 1212224A1 HK 16100181 A HK16100181 A HK 16100181A HK 1212224 A1 HK1212224 A1 HK 1212224A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pemetrexed formulation
- stabilized pemetrexed
- stabilized
- formulation
- pemetrexed
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 title 1
- 229960005079 pemetrexed Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120137375A KR101260636B1 (ko) | 2012-11-29 | 2012-11-29 | 안정화된 페메트렉시드 제제 |
PCT/KR2013/010967 WO2014084651A1 (en) | 2012-11-29 | 2013-11-29 | A stabilized pemetrexed formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1212224A1 true HK1212224A1 (en) | 2016-06-10 |
Family
ID=48665454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16100181.1A HK1212224A1 (en) | 2012-11-29 | 2016-01-08 | A stabilized pemetrexed formulation |
Country Status (16)
Country | Link |
---|---|
US (1) | US9265832B2 (de) |
EP (1) | EP2925325B1 (de) |
JP (1) | JP5934448B2 (de) |
KR (1) | KR101260636B1 (de) |
CN (1) | CN104812392B (de) |
AR (1) | AR093645A1 (de) |
BR (1) | BR112015012460B1 (de) |
CL (1) | CL2015001461A1 (de) |
ES (1) | ES2656901T3 (de) |
HK (1) | HK1212224A1 (de) |
JO (1) | JOP20130342B1 (de) |
MX (1) | MX355461B (de) |
PH (1) | PH12015500900A1 (de) |
RU (1) | RU2620341C2 (de) |
TW (1) | TWI498128B (de) |
WO (1) | WO2014084651A1 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102012010774A1 (de) * | 2012-05-31 | 2013-12-05 | Stada Arzneimittel Ag | Pharmazeutische Pemetrexed-Lösung |
KR101485243B1 (ko) * | 2013-05-08 | 2015-01-21 | 씨제이헬스케어 주식회사 | 안정화된 페메트렉시드 제제 |
JP6094388B2 (ja) * | 2013-06-07 | 2017-03-15 | ニプロ株式会社 | ペメトレキセドを含む注射用組成物 |
JP6313317B2 (ja) * | 2013-10-03 | 2018-04-18 | 富士フイルム株式会社 | 注射液製剤及びその製造方法 |
JP6120766B2 (ja) * | 2013-12-27 | 2017-04-26 | 富士フイルム株式会社 | 注射液製剤及びその製造方法 |
KR101703980B1 (ko) | 2013-12-30 | 2017-02-08 | 주식회사 삼양바이오팜 | 항산화제를 함유하지 않는 약학 조성물 및 그의 제조방법 |
EP3124026B1 (de) * | 2014-03-28 | 2018-07-25 | Fujifilm Corporation | Injektionspräparat und verfahren zur herstellung davon |
GB201418555D0 (en) * | 2014-10-16 | 2014-12-03 | Teva Gmbh | Pemetrexed formulations |
KR101770605B1 (ko) * | 2014-11-17 | 2017-08-23 | 동아에스티 주식회사 | 페메트렉시드 또는 그것의 약제학적으로 허용가능 한 염을 함유하는 안정한 약제학적 조성물 |
KR101919436B1 (ko) | 2015-05-28 | 2018-11-16 | 주식회사 삼양바이오팜 | 안정화된 약학 조성물 및 그의 제조방법 |
KR101693675B1 (ko) | 2015-12-14 | 2017-01-06 | 주식회사 종근당 | 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물 |
JP6837895B2 (ja) * | 2017-04-04 | 2021-03-03 | 日本化薬株式会社 | 医薬品溶液製剤の製造方法 |
US20200246263A1 (en) * | 2017-08-29 | 2020-08-06 | Fresenius Kabi Oncology Limited | Stable liquid compositions of pemetrexed |
KR102040034B1 (ko) | 2017-12-13 | 2019-11-05 | 주식회사 아이큐어비앤피 | 페메트렉시드를 포함하는 경구용 약학 조성물 및 이의 제조방법 |
US10966982B2 (en) | 2018-11-20 | 2021-04-06 | Cipla Limited | Stable pharmaceutical formulations of pemetrexed |
EP4132504A1 (de) * | 2020-04-09 | 2023-02-15 | Emphascience, Inc. | Behandlungsverfahren mit antifolaten und pharmazeutische formulierungen mit antifolaten |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0162654B1 (ko) | 1989-12-11 | 1998-11-16 | 알렌 제이. 시니스갤리 | N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체 |
CA2032695A1 (en) | 1989-12-20 | 1991-06-21 | Hiroshi Akimoto | Condensed heterocyclic compounds, their production and use |
TR200401436T4 (tr) * | 2000-02-04 | 2004-07-21 | Eli Lilly And Company | Monotiyogliserol, L-sistem veya tiyoglikolik asitle birlikte pemetrexed içeren farmasötik bileşim |
US6686365B2 (en) * | 2000-02-04 | 2004-02-03 | Eli Lilly And Company | Pharmaceutical composition |
KR100774366B1 (ko) | 2001-09-10 | 2007-11-08 | 주식회사 중외제약 | 파클리탁셀 주사제 조성물 |
CH697021A5 (de) * | 2003-06-26 | 2008-03-31 | Merck Eprova Ag | Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat. |
DE602004025151D1 (de) | 2004-03-10 | 2010-03-04 | Shimoda Biotech Pty Ltd | Stabile injizierbare Diclofenac- Zubereitungen |
ATE492547T1 (de) * | 2006-08-14 | 2011-01-15 | Sicor Inc | Verfahren zur herstellung lipophiler pharmazeutisch akzeptabler salze aus pemetrexed- disäure |
EP2072518A1 (de) * | 2007-12-23 | 2009-06-24 | Sun Pharma Advanced Research Company Limited | Stabile amorphe Form aus Pemextred Disodium |
WO2012015810A2 (en) | 2010-07-28 | 2012-02-02 | Eagle Pharmaceuticals, Inc. | Pharmaceutical compositions containing pemetrexed having extended storage stability |
KR101069128B1 (ko) * | 2011-03-10 | 2011-09-30 | 건일제약 주식회사 | 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법 |
DE102012010774A1 (de) * | 2012-05-31 | 2013-12-05 | Stada Arzneimittel Ag | Pharmazeutische Pemetrexed-Lösung |
KR101485243B1 (ko) * | 2013-05-08 | 2015-01-21 | 씨제이헬스케어 주식회사 | 안정화된 페메트렉시드 제제 |
-
2012
- 2012-11-29 KR KR1020120137375A patent/KR101260636B1/ko active IP Right Grant
-
2013
- 2013-11-27 JO JOP/2013/0342A patent/JOP20130342B1/ar active
- 2013-11-28 AR ARP130104389A patent/AR093645A1/es not_active Application Discontinuation
- 2013-11-28 TW TW102143402A patent/TWI498128B/zh active
- 2013-11-29 US US14/646,615 patent/US9265832B2/en active Active
- 2013-11-29 ES ES13858153.3T patent/ES2656901T3/es active Active
- 2013-11-29 RU RU2015122023A patent/RU2620341C2/ru active
- 2013-11-29 JP JP2015544000A patent/JP5934448B2/ja active Active
- 2013-11-29 WO PCT/KR2013/010967 patent/WO2014084651A1/en active Application Filing
- 2013-11-29 CN CN201380062109.1A patent/CN104812392B/zh active Active
- 2013-11-29 MX MX2015006325A patent/MX355461B/es active IP Right Grant
- 2013-11-29 EP EP13858153.3A patent/EP2925325B1/de active Active
- 2013-11-29 BR BR112015012460-7A patent/BR112015012460B1/pt active IP Right Grant
-
2015
- 2015-04-22 PH PH12015500900A patent/PH12015500900A1/en unknown
- 2015-05-29 CL CL2015001461A patent/CL2015001461A1/es unknown
-
2016
- 2016-01-08 HK HK16100181.1A patent/HK1212224A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US9265832B2 (en) | 2016-02-23 |
CN104812392A (zh) | 2015-07-29 |
TWI498128B (zh) | 2015-09-01 |
RU2620341C2 (ru) | 2017-05-24 |
WO2014084651A1 (en) | 2014-06-05 |
MX2015006325A (es) | 2016-02-25 |
EP2925325A4 (de) | 2016-07-13 |
JP5934448B2 (ja) | 2016-06-15 |
EP2925325B1 (de) | 2017-11-01 |
AR093645A1 (es) | 2015-06-17 |
RU2015122023A (ru) | 2017-01-10 |
MX355461B (es) | 2018-04-19 |
ES2656901T3 (es) | 2018-02-28 |
PH12015500900B1 (en) | 2015-07-06 |
CN104812392B (zh) | 2017-05-17 |
US20150297724A1 (en) | 2015-10-22 |
BR112015012460A2 (de) | 2017-08-22 |
PH12015500900A1 (en) | 2015-07-06 |
TW201434493A (zh) | 2014-09-16 |
BR112015012460B1 (pt) | 2022-04-05 |
CL2015001461A1 (es) | 2015-10-23 |
JOP20130342B1 (ar) | 2021-08-17 |
EP2925325A1 (de) | 2015-10-07 |
KR101260636B1 (ko) | 2013-05-13 |
JP2016500099A (ja) | 2016-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1212224A1 (en) | A stabilized pemetrexed formulation | |
AP2014007810A0 (en) | Imidazopyrrolidinone compounds | |
EP2828177A4 (de) | Spender | |
EP2925129A4 (de) | Pro-neurogene verbindungen | |
EP2832453A4 (de) | Zerstäuber | |
EP2887803A4 (de) | Pro-neurogene verbindungen | |
EP2934259A4 (de) | Spender | |
HK1218076A1 (zh) | 穩定的培美曲塞製劑 | |
GB201111438D0 (en) | Formulation | |
EP2828262A4 (de) | Imidazotriazinonverbindungen | |
ZA201309221B (en) | Formulation | |
ZA201404918B (en) | Stabilized pth formulation | |
EP2825475A4 (de) | Düse | |
HK1202445A1 (en) | New formulation | |
ZA201306000B (en) | Stable formulation | |
PT2879805T (pt) | Arranjo de bicos | |
EP2911563A4 (de) | Spender | |
EP2866626A4 (de) | Spender | |
PL2701506T3 (pl) | Składnik formulacji | |
ZA201402456B (en) | Formulation | |
GB201121377D0 (en) | Formulation component | |
GB201107039D0 (en) | Formulation component | |
ZA201501864B (en) | Dispensers | |
HUE039260T2 (hu) | Adagoló | |
HK1207351A1 (en) | Dispenser |